

Regensburg, Germany
26-28 November 2025

Wednesday, 26 November 2025

13:00 – 15:00	Session I: The Bone Marrow Niche in Haemoglobinopathies Chairs: <i>Emanuele Angelucci (IT) & Selim Corbacioglu (DE)</i>	
13:05 – 13:25	Ferroptosis and Iron Haemostasis in BM and Inflammation	Federica Pilo (IT)
13:25 – 13:55	Is SCD a pre-cancerous condition: Clonality in SCD	Michael S. Chapman (UK)
13:55 – 14:15	Ineffective erythropoiesis	Lucia de Franceschi (IT)
14:15 – 14:35	Recent advances in iron homeostasis	
14:35 – 15:00	Round table discussion: <i>Are the intrinsic features of these disorders making transplantation difficult?</i>	
15:00 – 15:30	Coffee Break	
15:30 – 16:00	Keynote Lecture Chair: <i>Josu de la Fuente (UK)</i> Advances in non-cellular therapies	Kevin Kuo (CA)
16:00 – 17:30	Session II: The problem of NTDT: an orphan haemoglobinopathy Chairs: <i>Federica Pilo (IT) & Miguel Abboud (LB)</i>	
16:00 – 16:20	Introduction and Natural History of NTDT	Nica Capellini (IT)
16:20 – 16:40	Mechanism of switch to transfusion dependence	Valeria Pinto (IT)
16:40 – 17:00	Modern treatment of NTDT	Donatella Baronciani (IT)
17:00 – 17:30	Round table discussion: <i>Is there a role for BMT or gene therapy (non-transplanter point of view)?</i>	
17:30 – 18:00	Poster Walk	

Thursday, 27 November 2025
Main Track

09:30 – 10:00	Roundtable discussion: <i>Are all approaches the same?</i>	
10:00 – 11:00	Session III (part I): Gene Editing, Gene Therapy, Gene Correction	
	Chairs:	
10:00 – 10:20	Update on Zynteglo for TDT	Franco Locatelli (IT)
10:20 – 10:40	Update on Lytfia for SCD	Julie Kanter (US)
10:40 – 11:00	Update on Casgevy for TDT	Josu de la Fuente (UK)
11:00 – 11:30	Coffee Break	
11:30 – 12:30	Session III (part II): Gene Editing, Gene Therapy, Gene Correction	
	Chairs:	
11:30 – 12:00	Update on Casgevy for SCD	Selim Corbacioglu (DE)
12:00 – 12:30	Update on BEACON study for SCD	Matthew Heeney (US)
12:30 – 13:15	Lunch Break	
13:15 – 14:15	Industry Symposium kindly sponsored by Vertex	
	Panel perspectives: Learnings from clinical experience across the patient journey	
13:15 – 13:25	Welcome and introduction	Roland Meisel (DE)
13:25 – 13:45	Optimising the patient journey for gene therapies: Lessons from clinical practice	Rabi Hanna (US)
13:45 – 13:15	Panel discussion and clinical perspectives	All
14:15 – 15:45	Session III (part III): Gene Editing, Gene Therapy, Gene Correction	
	Chairs: Rabi Hanna (US) & Julie Kanter (US)	
14:15 – 14:35	Strategies for successful apheresis collection and post dosing care	Akshay Sharma (US)
14:35 – 14:55	Getting to the 'sweet spot' exposure of Busulfan; minimal toxicity/optimal effect	Jaap Jan Boelens (US)
14:55 – 15:15	Immune reconstitution & long-term care management	
15:15 – 15:35	Real-world experience: REGENT	Sonali Choudhury (US)
15:35 – 15:45	Round table discussion: <i>What are the priorities for a successful programme?</i>	
15:45 – 16:15	Coffee Break	
16:15 – 17:00	Industry Symposium kindly sponsored by Miltenyi	
	Alpa-beta T-cell-depleted haploidentical stem cell transplantation, a valid alternative for adults and children suffering from hemoglobinopathies worldwide?	
16:15 – 16:30	aβ T cell-depleted grafts for adults and children with sickle cell disease	Selim Corbacioglu (DE)
16:30 – 16:45	TCR alpha/beta depleted haplo-identical transplants in transfusion dependent thalassemia: experience from India	Sunil Bhat (IN)
16:45 – 17:00	Discussion	Jaap Jan Boelens (US)
17:00 – 18:00	Session IV: Alternative Donor Transplantation	
	Chairs: Fabio Giglio (IT) & Matthew Heeney (US)	
17:00 – 17:20	PTCy RIC transplantation (for adults & children)	Adetola Kassim (US)
17:20 – 17:40	Managing mixed chimerism in aβ-depleted tx	Selim Corbacioglu (DE)
17:40 – 18:00	Patient selection for curative therapies	Monica Bathia (US)

Thursday, 27 November 2025 Nurses' Track

09:30 – 11:00	Session I (part I): Pre-transplant care Chairs: <i>Hilda Mekelenkamp (NL) & Sandrine Bremathas (UK)</i>	
09:30 – 09:40	Introductions	
09:40 – 10:00	Supportive care in sickle cell disease	
10:00 – 10:20	Supportive care in thalassaemia	Majken Høeg Olsen (DK)
10:20 – 10:40	Indication and outcomes of HSCT	Liesbeth Suijk (NL)
10:40 – 11:00	Preparation for standard HSCT	Hilda Mekelenkamp (NL)
11:00 – 11:30	Coffee Break	
11:30 – 12:30	Session I (part II): Pre-transplant care Chairs:	
11:30 – 11:50	Donor selection: use of haploidentical donors in haemoglobinopathies	
11:50 – 12:10	Use of pre transplant immunosuppression (PTIS) in TDT	Donatella Baronciani (IT)
12:10 – 12:30	Use of reduced toxicity regimens in patients (>16) with HLA matched siblings	
12:30 – 13:15	Lunch Break	
13:15 – 14:15	Industry Symposium kindly sponsored by Vertex (Main Room)	
14:15 – 15:45	Session II: Gene Editing, Gene Therapy, Gene Correction Chairs: <i>Liesbeth Suijk (NL)</i>	
14:15 – 14:35	Gene therapy: is this the new way forward?	Marjola Gjergji (IT)
14:35 – 14:55	Gene therapy preparation: how does it differ to HSCT preparation?	Sandrine Bremathas (UK)
14:55 – 15:15	Mobilisation and optimising stem cell collections	
15:15 – 15:35	Case study	
15:35 – 15:45	Updates from the clinical trials & future trials	Miguel Abboud (LB)
15:45 – 16:15	Coffee Break	
16:15 – 17:00	Industry Symposium kindly sponsored by Miltenyi (Main Room)	
17:00 – 18:00	Session III: The role of MDT members and patient perspective Chairs: <i>Hilda Mekelenkamp (NL) & Marjola Gjergji (IT)</i>	
17:00 – 17:20	Role of the clinical psychologist for patients with haemoglobinopathies	Becky Armstrong (UK)
17:20 – 17:40	Role of the physiotherapist in patients with haemoglobinopathies	
17:40 – 18:00	Patient perspective (TIF)	Loris Angelo Brunetta (IT)

Friday, 28 November 2025

08:00 – 09:30	Haemoglobinopathies Working Party Annual Meeting Business Meeting <i>Open to all.</i>	
09:30 – 11:00	Session V: Resource Limited Setting Chairs: <i>Fabio Gilgio (IT) & Miguel Abboud (LB)</i>	
09:30 – 09:45	Challenges & priorities of allogeneic transplantation in Tanzania	Stella Malangahe (TZ)
09:45 – 10:00	Challenges & priorities of allogeneic transplantation in Nigeria	Ugonna Fakile (NG)
10:00 – 10:15	Challenges & priorities of allogeneic transplantation in unequal settings	Lawrence Faulkner (IT)
10:15 – 10:30	Does gene therapy have a role in resource limited setting	Miguel Abboud (LB)
10:30 – 11:00	Roundtable discussion: <i>Is the role for curative therapies in resource limited settings?</i>	
11:00 – 11:30	Coffee Break	
11:30 – 13:00	Session VI: Alternative Donor Transplantation-Improving Outcomes Chairs: <i>Monica Bhatia (US)</i>	
11:30 – 11:50	The role of AI in transplantation	
11:50 – 12:10	Cerebrovascular disease: reversibility or stabilisation?	Francoise Bernaudin (FR)
12:10 – 12:30	Utility and outcomes of transplantation of psychometric tests	Becky Armstrong (UK)
12:30 – 12:50	Reversibility of iron damage	Emanuele Angelucci (IT)
12:50 – 13:00	Effect of BMT on sickle cell disease-related organ complications	Erfan Nur (NL)
13:00 – 13:30	Farewell Lunch	